Our top pick for
Building a portfolio
Arcturus Therapeutics Holdings Inc is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 118 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$17.20 - $129.71|
|50-day moving average||$45.30|
|200-day moving average||$61.83|
|Wall St. target price||$86.15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$9.5 million|
|Gross profit TTM||$-48,307,000|
|Return on assets TTM||-16%|
|Return on equity TTM||-34.17%|
|Market capitalisation||$1 billion|
TTM: trailing 12 months
There are currently 3.8 million Arcturus Therapeutics shares held short by investors – that's known as Arcturus Therapeutics's "short interest". This figure is 18.8% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Arcturus Therapeutics shares can be evaluated.
Arcturus Therapeutics's "short interest ratio" (SIR) is the quantity of Arcturus Therapeutics shares currently shorted divided by the average quantity of Arcturus Therapeutics shares traded daily (recently around 757603.01810865). Arcturus Therapeutics's SIR currently stands at 4.97. In other words for every 100,000 Arcturus Therapeutics shares traded daily on the market, roughly 4970 shares are currently held short.
However Arcturus Therapeutics's short interest can also be evaluated against the total number of Arcturus Therapeutics shares, or, against the total number of tradable Arcturus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcturus Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Arcturus Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.182% of the tradable shares (for every 100,000 tradable Arcturus Therapeutics shares, roughly 182 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arcturus Therapeutics.
Find out more about how you can short Arcturus Therapeutics stock.
We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.
Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.
Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $17.2 up to $129.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.8089. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc.
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.